期刊文献+

沙利度胺治疗慢性病贫血临床研究

Clinical Research of Thalidomide for the Treatment of Anemia of Chronic Disease
下载PDF
导出
摘要 目的:评估沙利度胺治疗慢性病贫血的临床疗效,观察其不良反应。方法:对2011年3月至2011年10月我院26例慢性病贫血患者的临床资料进行分析,采用沙利度胺治疗,必要时输注红细胞纠正贫血。结果:26例患者中有效15例,有效率57.7%,无效11例,无效率42.3%,其中死亡2例。结论:沙利度胺治疗慢性病贫血有较好疗效,不良反应小,值得进一步推广。 Objective :To estimate the clinical effect of thalidomide in treating anemia of chronic disease (ACD) and observe its adverse reactions. Methods:26 patients diagnosed as ACD from March, 2011 to October, 2011 were treated with thalidomide and injected with red blood cell (RBC) for treating anemia necessarily. Results: 15 patients had achieved good remission, the remission rate was 57.7%, while 11 patients had achieved no effect, the un-effective rate was 42.3%, 2 patients died. Conclusion:Thalidomide is an effective and safe drug in treating ACD with side effects being mild, so it is worth further spreading.
出处 《赣南医学院学报》 2012年第2期231-232,共2页 JOURNAL OF GANNAN MEDICAL UNIVERSITY
基金 2011年赣州市指导性科技计划项目(编号:178)
关键词 沙利度胺 慢性病贫血 ACD Thalidomide Anemia of chronic disease ACD
  • 相关文献

参考文献4

  • 1D~mato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis[ J]. Proc Natl Acad Sci USA, 1994,91 (9) :4082-4085.
  • 2Huang F,Wei JC,Breban M.Thalidomide in ankylosingspondylitis[J].Clin Exp Rheumatol,2002,20(Suppl28):S158-S161.
  • 3Deng L,Ding W,Granstein RD.Thalidomide inhibitstumor necrosis factor-alpha production and antigen pres-entation by Langerhas cells[J].J Invest Dermatol,2003,121(5):1060-1065.
  • 4白楠,李晓娇,梁蓓蓓,蔡芸,宋秀杰,于旭红,刘浩,刘哲元,王睿.沙利度胺临床新用途研究文献计量分析[J].中国药物应用与监测,2010,7(4):242-246. 被引量:4

二级参考文献14

  • 1Matthews SJ,McCoy C.Thalidomide:a review of approved and investigational uses[J].Clin Ther,2003,25(2):342-395.
  • 2Karim MY,Ruiz-Irastorza G,Khamashta MA,et al.Update on therapy-thalidomide in the treatment of lupus[J].Lupus,2001,10(3):188-192.
  • 3Shimanovich I,Merl V,Zillikens D,et al.Two faces of Janus.Coexistence of systemic lupus erythematosus and psoriasis in the same patient[J].Hautarzt,2009,61(1):58-63.
  • 4Gutiérrez-Rodríguez O.Thalidomide:a promising new treatment for rheumatoid arthritis[J[.Arthritis Rheum,1984,27(10):1118-1121.
  • 5Wei JC,Chan TW,Lin HS,et al.Thalidomide for severe refractory ankylosing spondylitis:a 6-month open-label trial[J].J Rheumatol,2003,30(12):2627-2631.
  • 6Akkoc N,van der Linden S,Khan MA.Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy[J].Best Pract Res Clin Rheumatol,2006,20(3):539-557.
  • 7Palumbo A,Rajkumar SV.Multiple myeloma:chemotherapy or transplantation in the era of new drugs[J].Eur J Haematol,2010,84(5):379-390.
  • 8D'Amato RJ,Loughnan MS,Flynn E,et al.Thalidomide is an inhibitor of angiogenesis[J].Proc Natl Acad Sci USA,1994,91(9):4082-4085.
  • 9Deng L,Ding W,Granstein RD.Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells[J].J Invest Dermatol,2003,121(5):1060-1065.
  • 10Verma A,List AF.Cytokine targets in the treatment of myelodysplastic syndromes[J].Curr Hematol Rep,2005,4(6):429-435.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部